Abstract
Nicotinic α7 receptors have been shown in a variety of studies with animal models to play important roles in diverse components of cognitive function, including learning, memory and attention. Mice with α7 receptor knockouts show impairments in memory. Selective α7 agonists significantly improve learning, memory and attention. α7 receptors in limbic structures such as the hippocampus and amygdala have been demonstrated to play critical roles in memory. Blockade of α7 receptors in these areas cause memory impairments. In the brains of people with schizophrenia α7 receptors are impaired. This may be related to pronounced cognitive impairments seen with schizophrenia. There has been a major effort to develop α7 nicotinic agonists for helping to reverse cognitive impairment. These receptors are a promising target for development of therapeutic treatments for a variety of diseases of cognitive impairment including Alzheimer’s disease, attention deficit hyperactivity disorder (ADHD) and schizophrenia.
Keywords: α7-Nicotinic Receptors, memory, learning, attention, cognition, α7 agonist, deficit models, ADHD, Alzheimer's disease, Schizophrenia
Current Drug Targets
Title:α7-Nicotinic Receptors and Cognition
Volume: 13 Issue: 5
Author(s): Edward D. Levin
Affiliation:
Keywords: α7-Nicotinic Receptors, memory, learning, attention, cognition, α7 agonist, deficit models, ADHD, Alzheimer's disease, Schizophrenia
Abstract: Nicotinic α7 receptors have been shown in a variety of studies with animal models to play important roles in diverse components of cognitive function, including learning, memory and attention. Mice with α7 receptor knockouts show impairments in memory. Selective α7 agonists significantly improve learning, memory and attention. α7 receptors in limbic structures such as the hippocampus and amygdala have been demonstrated to play critical roles in memory. Blockade of α7 receptors in these areas cause memory impairments. In the brains of people with schizophrenia α7 receptors are impaired. This may be related to pronounced cognitive impairments seen with schizophrenia. There has been a major effort to develop α7 nicotinic agonists for helping to reverse cognitive impairment. These receptors are a promising target for development of therapeutic treatments for a variety of diseases of cognitive impairment including Alzheimer’s disease, attention deficit hyperactivity disorder (ADHD) and schizophrenia.
Export Options
About this article
Cite this article as:
Edward D. Levin , α7-Nicotinic Receptors and Cognition , Current Drug Targets 2012; 13 (5) . https://dx.doi.org/10.2174/138945012800398937
DOI https://dx.doi.org/10.2174/138945012800398937 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Understanding Effects of Psychological Stress on Physiology and Disease Through Human Stressome - An Integral Algorithm
Current Bioinformatics Pharmacological Medical Treatment of Epilepsy in Patients with Dementia: A Systematic Review
Current Alzheimer Research Editorial [Hot Topic: Anticonvulsant Agents (Guest Editor: Barbara Malawska)]
Current Topics in Medicinal Chemistry Disorders of Consciousness and Electrophysiological Treatment Strategies: A Review of the Literature and New Perspectives
Current Pharmaceutical Design Targeting the Role of Astrocytes in the Progression of Alzheimers Disease
Current Signal Transduction Therapy Cognitive Identity in Schizophrenia: Vision, Space, and Body Perception from Prodrome to Syndrome
Current Psychiatry Reviews The Renin-Angiotensin System: New Insight into Old Therapies
Current Medicinal Chemistry Recent Development in Substituted Benzothiazole as an Anticonvulsant Agent
Mini-Reviews in Medicinal Chemistry Distinct Forms of Spinal Cysticercosis: A Vietnamese Case Series
Current Medical Imaging Editorial [Hot Topic: Adenosine-Based Modulation of Brain Activity (Guest Editor: DETLEV BOISON)]
Current Neuropharmacology Biomarkers of Alzheimer’s Disease: An Overview of the Recent Inventions
Recent Patents on Biomarkers Developmental Expression and Dysregulation of miR-146a and miR-155 in Down's Syndrome and Mouse Models of Down's Syndrome and Alzheimer's Disease
Current Alzheimer Research TRPC Channels and their Implications for Neurological Diseases
CNS & Neurological Disorders - Drug Targets Carbohydrate-Based Bioactive Compounds for Medicinal Chemistry Applications
Mini-Reviews in Medicinal Chemistry Central Serotonin2C Receptor: From Physiology to Pathology
Current Topics in Medicinal Chemistry Geriatric Psychopharmacology in Acute Settings
Current Psychopharmacology Medical Treatment for Neurocysticercosis: Drugs, Indications and Perspectives
Current Topics in Medicinal Chemistry Crosstalk Between Calpain and Calcineurin in Excitotoxic Neurodegeneration; Therapeutic Targets for the Treatment of Excitotoxic Neurodegeneration
Current Medicinal Chemistry - Central Nervous System Agents Genomic Expression in the Epileptogenic Hippocampus and Psychiatric Co-Morbidities
Current Psychiatry Reviews Systemic Redox Biomarkers in Neurodegenerative Diseases
Current Drug Metabolism